Huntington's Disease Treatment Market Research Report Information by drug type (tetrabenazinedeutetrabenazine, chlorpromazine and others), Treatment (symptomatic therapy, disease-modifying therapy), End-users (hospital and others) - Forecast Till 2032

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Huntington’s Disease Treatment Market, by Drug Type

6.1 Introduction

6.2 Tetrabenazine

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Deutetrabenazine

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.4 Selective Serotonin Reuptake Inhibitor (SSRI)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.5 Chlorpromazine

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.6 Haloperidol

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.7 Risperidone

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.8 Olanzapine

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.9 Clozapine

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.10 Other

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Huntington’s Disease Treatment Market, by Treatment

7.1 Introduction

7.2 Symptomatic therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Disease-Modifying therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Huntington’s Disease Treatment Market, by End-Users

8.1 Introduction

8.2 Hospital

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Retail Pharmacies

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.5 Online Pharmacies

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.6 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Huntington’s Disease Treatment Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Pfizer, Inc.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Alnylam Pharmaceuticals Inc

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 AmpliPhi Biosciences Corp

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Ceregene Inc

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Prana Biotechnology Limited

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Teva Pharmaceutical Industries Ltd

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Cortex Pharmaceuticals Inc

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Vertex Pharmaceuticals Incorporated

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Auspex Pharmaceuticals

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 SOM Biotech

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 GlaxoSmithKline

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Siena Biotech

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 Raptor Pharmaceutical

11.13.1 Overview

11.13.2 Product Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 Palobiofarma

11.14.1 Overview

11.14.2 Product Overview

11.14.3 Financials

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.15 Omeros

11.15.1Overview

11.15.2 Product Overview

11.15.3 Financials

11.15.4 Key Developments

11.15.5 SWOT Analysis

11.16 Ipsen

11.16.1 Overview

11.16.2 Product Overview

11.16.3 Financials

11.16.4 Key Developments

11.16.5 SWOT Analysis

11.17 Valeant Pharmaceuticals International Inc

11.17.1 Overview

11.17.2 Product Overview

11.17.3 Financials

11.17.4 Key Developments

11.17.5 SWOT Analysis

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Global Huntington’s Disease Treatment Market

Chapter 13. Appendix

LIST OF TABLES

Table 1 Global Huntington’s Disease Treatment Market Synopsis, 2020-2027

Table 2 Global Huntington’s Disease Treatment Market Estimates and Forecast, 2020-2027 (USD Million)

Table 3 Global Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

Table 4 Global Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 5 Global Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

Table 6 Global Huntington’s Disease Treatment Market, by Region, 2020-2027(USD Million)

Table 7 North America: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

Table 8 North America: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 9 North America: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

Table 10 North America: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

Table 11 US: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

Table 12 US: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 13 US: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

Table 14 US: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

Table 15 Canada: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

Table 16 Canada: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 17 Canada: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

Table 18 Canada: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

Table 19 South America: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

Table 20 South America: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 21 South America: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

Table 22 South America: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

Table 23 Europe: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

Table 24 Europe: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 25 Europe: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

Table 26 Europe: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

Table 27 Western Europe: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

Table 28 Western Europe: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 29 Western Europe: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

Table 30 Western Europe: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

Table 31 Eastern Europe: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

Table 32 Eastern Europe: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 33 Eastern Europe: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

Table 34 Eastern Europe: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

Table 35 Asia-Pacific: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

Table 36 Asia-Pacific: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 37 Asia-Pacific: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

Table 38 Asia-Pacific: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

Table 39 Middle East & Africa: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

Table 40 Middle East & Africa: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 41 Middle East & Africa: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

Table 42 Middle East & Africa: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Huntington’s Disease Treatment Market

Figure 3 Segmentation Market Dynamics for Global Huntington’s Disease Treatment Market

Figure 4 Global Huntington’s Disease Treatment Market Share, by Drug Type, 2020(%)

Figure 5 Global Huntington’s Disease Treatment Market Share, by Treatment, 2020(%)

Figure 6 Global Huntington’s Disease Treatment Market Share, by End-Users, 2020(%)

Figure 7 Global Huntington’s Disease Treatment Market Share, by Region, 2020(%)

Figure 8 North America: Huntington’s Disease Treatment Market Share, by Country, 2020(%)

Figure 9 Europe: Huntington’s Disease Treatment Market Share, by Country, 2020(%)

Figure 10 Asia-Pacific: Huntington’s Disease Treatment Market Share, by Country, 2020(%)

Figure 11Middle East & Africa: Huntington’s Disease Treatment Market Share, by Country,2020(%)

Figure 12 Global Huntington’s Disease Treatment Market: Company Share Analysis, 2020(%)

Figure 13 Pfizer, Inc: Key Financials

Figure 14 Pfizer, Inc: Segmental Revenue

Figure 15 Pfizer, Inc: Geographical Revenue

Figure 16 Alnylam Pharmaceuticals Inc: Key Financials

Figure 17 Alnylam Pharmaceuticals Inc: Segmental Revenue

Figure 18 Alnylam Pharmaceuticals Inc: Geographical Revenue

Figure 19 AmpliPhi Biosciences Corp: Key Financials

Figure 20 AmpliPhi Biosciences Corp: Segmental Revenue

Figure 21 AmpliPhi Biosciences Corp: Geographical Revenue

Figure 22 Ceregene Inc: Key Financials

Figure 23 Ceregene Inc: Segmental Revenue

Figure 24 Ceregene Inc: Geographical Revenue

Figure 25 Prana Biotechnology Limited.: Key Financials

Figure 26 Prana Biotechnology Limited.: Segmental Revenue

Figure 27 Prana Biotechnology Limited.: Geographical Revenue

Figure 28 Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 29 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 30 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 31 Cortex Pharmaceuticals Inc: Key Financials

Figure 32 Cortex Pharmaceuticals Inc: Segmental Revenue

Figure 33 Cortex Pharmaceuticals Inc: Geographical Revenue

Figure 34 Vertex Pharmaceuticals Incorporated: Key Financials

Figure 35 Vertex Pharmaceuticals Incorporated: Segmental Revenue

Figure 36 Vertex Pharmaceuticals Incorporated: Geographical Revenue

Figure 37 Auspex Pharmaceuticals: Key Financials

Figure 38 Auspex Pharmaceuticals: Segmental Revenue

Figure 39 Auspex Pharmaceuticals: Geographical Revenue

Figure 40 SOM Biotech: Key Financials

Figure 41 SOM Biotech: Segmental Revenue

Figure 42 SOM Biotech: Geographical Revenue

Figure 43 GlaxoSmithKline: Key Financials

Figure 44 GlaxoSmithKline: Segmental Revenue

Figure 45 GlaxoSmithKline: Geographical Revenue

Figure 46 Siena Biotech: Key Financials

Figure 47 Siena Biotech: Segmental Revenue

Figure 48 Siena Biotech: Geographical Revenue

Figure 49 Raptor Pharmaceutical.: Key Financials

Figure 50 Raptor Pharmaceutical.: Segmental Revenue

Figure 51 Raptor Pharmaceutical.: Geographical Revenue

Figure 52 Palobiofarma: Key Financials

Figure 53 Palobiofarma: Segmental Revenue

Figure 54 Palobiofarma: Geographical Revenue

Figure 55 Omeros: Key Financials

Figure 56 Omeros: Segmental Revenue

Figure 57 Omeros: Geographical Revenue

Figure 58 Ipsen: Key Financials

Figure 59 Ipsen: Segmental Revenue

Figure 60 Ipsen: Geographical Revenue

Figure 61 Valeant Pharmaceuticals International Inc: Key Financials

Figure 62 Valeant Pharmaceuticals International Inc: Segmental Revenue

Figure 63 Valeant Pharmaceuticals International Inc: Geographical Revenue